Visual Outcomes and Associated Risk Factors for Blindness in Axenfeld–Rieger Syndrome - 01/09/26
Highlights |
• | In ARS glaucoma eyes, blindness reached 19.2% at 3 years, 27.5% at 5 years, and 36.3% at 10 years. |
• | About one-quarter of ARS glaucoma patients developed bilateral blindness. |
• | Presence of FOXC1 mutations within a family was associated with unfavorable visual outcomes. |
• | Blindness risk in ARS glaucoma: poor VA, high IOP, surgeries, cloudy cornea, female, Asian. |
Résumé |
Purpose |
To evaluate long-term visual outcomes in Axenfeld–Rieger syndrome (ARS), quantify blindness rates, and identify risk factors of blindness in ARS-related glaucoma.
Design |
Retrospective cohort study.
Methods |
Consecutive surgically naïve ARS patients diagnosed before age 18 at three tertiary hospitals in Thailand and the United States (2004-2023) were included. Visual status was classified per World Health Organization criteria. Outcomes were proportions of visual impairment/blindness at baseline and final follow-up, progression to blindness at 3, 5, and 10 years, and risk factors.
Results |
Ninety-six patients (189 eyes; mean age 4.05 ± 5.35 years) were followed for 8.72 ± 5.76 years. Glaucoma developed in 55.5% of eyes. Among glaucomatous eyes, 17.4% were blind at presentation; blindness progressed to 19.2% at 3 years, 27.5% at 5 years, and 36.3% at 10 years. Bilateral blindness occurred in 23.5% of glaucoma patients. Pathogenic FOXC1 variants were identified in 2 of 5 families, all with at least moderate impairment. Risk factors of blindness included poor initial visual acuity (AoR = 9.72, P = .002), higher intraocular pressure (IOP) (AoR = 1.153, P = .020), number of glaucoma surgeries (AoR = 1.92, P < .001), cloudy cornea (AoR = 4.42, P = .001), female sex (AoR = 6.36, P = .017), and Asian ethnicity (AoR = 6.06, P = .027).
Conclusions |
Nearly 40% of ARS eyes with glaucoma develop blindness within 10 years. Risk factors include poor VA, elevated IOP, number of glaucoma surgeries, cloudy cornea, female sex, and Asian ethnicity. Early detection, aggressive IOP control, and close monitoring are critical to preserve vision.
Le texte complet de cet article est disponible en PDF.Plan
| Supplemental Material available at AJO.com . |
|
| Meeting Presentations: United Kingdom Paediatric Glaucoma Society Annual Meeting on January 23, 2026, in London, UK. |
Vol 290
P. 9-16 - octobre 2026 Retour au numéro
Article précédent
- Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes
- Paulina Liberman, Sophia E. Yu, Israel J. Mendez, Eugenia M. Ramos, Meghan K. Berkenstock, Bryn M. Burkholder, Jennifer E. Thorne, Douglas A. Jabs
- Clinical Outcomes and Genomic Epidemiology of Multidrug-Resistant Methicillin-Resistant Staphylococcus aureus Keratitis
- Olivia W. Cummings, Camille Andre, Jennifer Ling, Sonia N. Yeung, Anastasia Faggioni, Alfonso Iovieno, Paulo J.M. Bispo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?